Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* Documented (cytologically confirmed) relapsed/ refractory Lymphoma or B-cell Acute Lymphocytic Leukemia (Philadelphia chromosome negative)~* ECOG Performance Status score of 0, 1, or 2 (see Attachment 1)~* Expected survival, in the opinion of the Investigator, of at least 3 months, to allow a sufficient observation period for evaluation of ON 013105~* Recovery to at least grade I from adverse effects of prior therapies~* Adequate contraceptive \[including prescription oral contraceptives (birth control pills), contraceptive injections, intrauterine device (IUD), double-barrier method (spermicidal jelly or foam with condoms or diaphragm), contraceptive patch, or surgical sterilization\] before entry and throughout the study for female patients of reproductive potential~* Female patient with reproductive potential must have a negative serum beta-HCG pregnancy test at screening~* Willing to adhere to the prohibitions and restrictions specified in this protocol~* Patient (or his/her legally authorized representative) must have signed an informed consent document indicating that he/she understands the purpose of and procedures required for the study and is willing to participate in the study~Exclusion Criteria:~* Grade 3 thrombocytopenia (platelets \<50,000/µL) or neutropenia (ANC \<1000/µL) ) except if documented evidence of bone marrow involvement of lymphoma or leukemia contributing to cytopenias.~* Any active malignancy within the past year except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix or breast~* History of HIV-1 seropositivity~* Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia~* Active infection not adequately responding to appropriate therapy.~* Total bilirubin \> 1.5 mg/dL not related to hemolysis or Gilbert's disease, AST/ALT \> 1.5 X ULN~* Serum creatinine \> 1.5 mg/dL or calculated creatinine clearance \< 60 ml/min.~* Ascites requiring active medical management including paracentesis, or hyponatremia (defined as serum sodium value of \<130 Meq/L).~* Women patients who are pregnant or lactating~* Male patients with female sexual partners who are unwilling to follow the strict contraception requirements described in this protocol (see Section 4.4).~* Major surgery without full recovery or major surgery within 3 weeks of ON 013105 treatment start.~* Uncontrolled hypertension (defined as a systolic pressure ³ 180 and/or a diastolic pressure ³ 110)~* New onset seizures (within 3 months prior to the first dose of ON 013105) or poorly controlled seizures~* Any concurrent investigational agent or chemotherapy, radiotherapy or immunotherapy~* Psychiatric illness/social situations that would limit the patient's ability to tolerate and/or comply with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ON 013105 (Type: EXPERIMENTAL): ON 013105 administered intravenously as 2-hour infusion once a week for 3 weeks of 3-week cycles. This is dose escalation study; starting dose is 17 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).